6T4 Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Trevena, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.83 |
| 52 Week High | US$16.15 |
| 52 Week Low | US$3.62 |
| Beta | 1.07 |
| 1 Month Change | 0% |
| 3 Month Change | -7.83% |
| 1 Year Change | -69.40% |
| 3 Year Change | -99.21% |
| 5 Year Change | -99.05% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6T4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | -0.5% |
| 1Y | -69.4% | -6.0% | 15.5% |
Return vs Industry: 6T4 underperformed the German Biotechs industry which returned -16.1% over the past year.
Return vs Market: 6T4 underperformed the German Market which returned 12.9% over the past year.
Price Volatility
| 6T4 volatility | |
|---|---|
| 6T4 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 6T4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6T4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 23 | Carrie Bourdow | www.trevena.com |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc. Fundamentals Summary
| 6T4 fundamental statistics | |
|---|---|
| Market cap | €1.52m |
| Earnings (TTM) | -€31.76m |
| Revenue (TTM) | €509.42k |
3.0x
P/S Ratio0.0x
P/E RatioIs 6T4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6T4 income statement (TTM) | |
|---|---|
| Revenue | US$546.00k |
| Cost of Revenue | US$1.59m |
| Gross Profit | -US$1.04m |
| Other Expenses | US$33.00m |
| Earnings | -US$34.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -39.40 |
| Gross Margin | -190.48% |
| Net Profit Margin | -6,233.70% |
| Debt/Equity Ratio | -141.0% |
How did 6T4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/09 08:49 |
| End of Day Share Price | 2024/08/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trevena, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Jonathan Aschoff | Brean Capital |
| Ritu Baral | Canaccord Genuity |